Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY: MRK )

99.18 -0.68 (-0.68%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
95 96 Next >
Hope for Kidney Cancer Patients, Merck's Keytruda Cuts Risk Of Death By 38% Following Surgery
Results from Merck's Phase 3 KEYNOTE-564 trial. Keytruda, an adjuvant treatment for renal cell carcinoma, shows a 38% improvement in overall survival at 57.2 months. 
Via Benzinga
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
A Bull Market Is Here: 2 Stocks to Buy and Hold for 10 Years
These companies can perform well through this bull run and beyond. 
Via The Motley Fool
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy
From Merck & Co., Inc.
Via Business Wire
Merck's Multi-Billion Cancer Drug Keytruda Improves Disease-Free Survival In Advanced Bladder Cancer After Surgery, Data Shows
Merck's Keytruda results in treating high-risk urothelial carcinoma. Discover statistically significant improvements in disease-free survival at ASCO GU Cancers Symposium 2024. 
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat)
The Benzinga Stock Whisper Index provides a look at five stocks that saw increased attention from traders over the past week. 
Via Benzinga
Topics Government
Exposures Political
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery
From Merck & Co., Inc.
Via Business Wire
Why Is Cancer Focused LAVA Therapeutics Nano Cap Stock Trading Higher Today?
LAVA Therapeutics collaborates with Merck on a clinical trial for anti-PD-1 therapy Keytruda in metastatic castration-resistant prostate cancer. 
Via Benzinga
3 S&P 500 Stocks With 127% to 170% Upside in 2024, According to Select Wall Street Analysts
Wall Street's benchmark index is comprised of 500 companies, three of which could deliver triple-digit upside in the new year. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Why Is Cancer Therapy Focused Evaxion Biotech Stock Trading Higher Today?
Evaxion Biotech revolutionizes cancer vaccine development, targeting AI-identified ERVs. Preclinical activities underway; Proof-of-Concept data expected by 2H 2024. 
Via Benzinga
3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom
These three aging stocks offer different thematic approaches to profit from the opportunities that exist in an aging population. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers on Tuesday with a breakdown of all the latest news affecting shares this morning. 
Via InvestorPlace
Merck Announces Second-Quarter 2024 Dividend
From Merck & Co., Inc.
Via Business Wire
This 1 Bullish Move by Merck Could Drive Growth for Years to Come
It's buying a company with sophisticated biotechnology platforms that could drive lots of growth -- eventually. 
Via The Motley Fool
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD. 
Via Talk Markets
Gilead Sciences Stock Crashes 9% After Cancer Drug Fails A Key Test
The company had hoped Trodelvy would extend overall survival for patients with a form of lung cancer. 
Via Investor's Business Daily
7 Exciting Stocks Poised for Explosive Growth in Key Sectors
These stocks to buy for growth already have a strong growth story. If they reach their potential investors could see some dynamic returns. 
Via InvestorPlace
Week in Review: Lee’s Pharma Signs $138 Million Agreement For China Rights To Heart Failure Therapy
Lee’s Pharma acquired China rights to a heart failure therapy from Windtree Therapeutics. Meanwhile, AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech... 
Via Talk Markets
S&P 500 Shatters Records: The Top-Performing Stocks In January 2024
2023 was a historical milestone for S&P 500 as it once again surpassed record highs, largely due to tech giants and artificial intelligence. Top gainers were NVIDIA, Meta Platforms, and AMD. 
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Amgen's Blockbuster Osteoporosis Drug Prolia Flagged With FDA Strictest Warning
FDA issues serious warning on Amgen's Prolia drug, highlighting increased risk of low calcium levels in specific patient groups. 
Via Benzinga
Exposures Product Safety
Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1
From Merck & Co., Inc.
Via Business Wire
Why Is Cancer Focused Adagene Stock Plummeting Today?
Adagene presents results at ASCO 2024 Gastrointestinal Cancers Symposium. ADG126, combined with Merck's Keytruda, shows limited toxicity, sustained partial responses, and a 22% overall response rate in... 
Via Benzinga
The 3 Best Dividend Growth Stocks to Buy in January 2024
These are the best dividend growth stocks to buy as they represent companies with healthy free cash flow upside visibility. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Merck's Crown Jewel Cancer Drug Keytruda Scores FDA Approval For Third Indication In Cervical Cancer
FDA approves Merck's Keytruda for advanced cervical cancer. Keytruda plus chemoradiotherapy shows a 41% improvement in progression-free survival. 
Via Benzinga
Exposures Product Safety
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
7 Healthcare Stocks Taking Medicine to the Next Level
With advances in technology potentially able to improve the human condition, these are the compelling healthcare stocks to consider. 
Via InvestorPlace
These 9 Stocks Are Running To Start 2024
The S&P 500 is up just 0.2% in 2024. These stocks are off to a strong start. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut. 
Via Investor's Business Daily
Topics ETFs
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
95 96 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.